These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 31102087)
21. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Takahashi N; Kojima T; Terabe K; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Ishikawa H; Hayashi M; Tsuboi S; Kato D; Funahashi K; Matsubara H; Hattori Y; Hanabayashi M; Hirabara S; Yoshioka Y; Ishiguro N Mod Rheumatol; 2013 Sep; 23(5):904-12. PubMed ID: 22975734 [TBL] [Abstract][Full Text] [Related]
22. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52. Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408 [TBL] [Abstract][Full Text] [Related]
23. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Keystone EC; Ahmad HA; Yazici Y; Bergman MJ Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995 [TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study. Tanaka Y; Matsubara T; Hashizume K; Amano N; Takeuchi T Mod Rheumatol; 2022 Apr; 32(3):500-507. PubMed ID: 34897499 [TBL] [Abstract][Full Text] [Related]
26. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice. Kaneko A; Hirano Y; Fujibayashi T; Hattori Y; Terabe K; Kojima T; Ishiguro N Mod Rheumatol; 2013 May; 23(3):466-77. PubMed ID: 22895833 [TBL] [Abstract][Full Text] [Related]
27. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H; J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689 [TBL] [Abstract][Full Text] [Related]
28. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Cannon GW; Mikuls TR; Hayden CL; Ying J; Curtis JR; Reimold AM; Caplan L; Kerr GS; Richards JS; Johnson DS; Sauer BC Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1680-90. PubMed ID: 21905260 [TBL] [Abstract][Full Text] [Related]
29. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Takeuchi T; Matsubara T; Ohta S; Mukai M; Amano K; Tohma S; Tanaka Y; Yamanaka H; Miyasaka N Rheumatology (Oxford); 2015 Apr; 54(4):683-91. PubMed ID: 25257039 [TBL] [Abstract][Full Text] [Related]
30. Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. Kubo S; Nakayamada S; Nakano K; Sawamukai N; Hirata S; Hanami K; Saito K; Tanaka Y Clin Immunol; 2018 Jun; 191():67-74. PubMed ID: 29614335 [TBL] [Abstract][Full Text] [Related]
31. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005 [TBL] [Abstract][Full Text] [Related]
32. Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. Ahmad HA; Baker JF; Østergaard M; Emery P; Durez P; Ye J; Banerjee S; Conaghan PG Arthritis Care Res (Hoboken); 2020 Jul; 72(7):959-964. PubMed ID: 31549793 [TBL] [Abstract][Full Text] [Related]
33. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865 [TBL] [Abstract][Full Text] [Related]
34. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. Mary J; De Bandt M; Lukas C; Morel J; Combe B J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710 [TBL] [Abstract][Full Text] [Related]
35. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Sokolove J; Schiff M; Fleischmann R; Weinblatt ME; Connolly SE; Johnsen A; Zhu J; Maldonado MA; Patel S; Robinson WH Ann Rheum Dis; 2016 Apr; 75(4):709-14. PubMed ID: 26359449 [TBL] [Abstract][Full Text] [Related]
36. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438 [TBL] [Abstract][Full Text] [Related]
37. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET). Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520 [TBL] [Abstract][Full Text] [Related]
38. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis. Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919 [TBL] [Abstract][Full Text] [Related]
39. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382 [TBL] [Abstract][Full Text] [Related]
40. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE; Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]